AbbVie Inc. ‘s third quarter earnings came in at $3.66 per share for the third quarter of 2022 (up +29.3% from the year-ago quarter), exceeding the Zacks Consensus Estimate of $3.56 per share.
Revenues rose +3.3% year-over-year to $14.81 billion, missing the Zacks Consensus Estimate of $14.92 billion.
In immunology, AbbVie’s flagship drug Humira experienced a 3.9% sales growth to $5.56 billion on an operational basis. Sales in the U.S. grew +7.4% to $4.96 billion, vs. the -16.8% decline in ex-U.S. market sales.
AbbVie narrowed the full-year 2022 adjusted earnings per share guidance range to $13.84-$13.88, from the prior guidance of $13.78-$13.98. The Zacks Consensus Estimate is $13.89 per share.
ABBV moved above its 50-day moving average on September 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 54 cases where ABBV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 49 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
Following a +1.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 218 of 359 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 21 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 45%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (243.902) is very high in comparison to the industry average of (19.199). ABBV has a moderately high P/E Ratio (75.220) as compared to the industry average of (34.793). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.026) settles around the average of (0.025) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a research-based pharmaceutical company
Industry PharmaceuticalsMajor